RxDoctor Payments Data

Kathleen Robinson, NP

Acute Care · Warwick, RINPI 1235553264

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Johnson & Johnson at 36.5% of the total.

$399in general payments, 2019–2025

Across 7 payments — averaging $57.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$146
  • AstraZeneca$117
  • Kiniksa Pharmaceuticals International, PLC$62
  • Pfizer$37
  • Scilex Pharmaceuticals Inc.$24
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14
$41,172in research payments, 2019–2025

Across 11 payments — averaging $3742.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Karyopharm Therapeutics Inc.$41K

What the payments were for

  • Food & beverage$399100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$399 in reported general payments places this provider in the 60th percentile of 66 acute care providers in Rhode Island.

See all acute care providers in Rhode Island

Medicare billing

Part B allowed, 2024
$8,736
Medicare patients
92
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$18,389
Metoprolol Succinate61$585
Atorvastatin Calcium46$535
Ezetimibe36$382
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$316
Amlodipine Besylate33$271
Losartan Potassium14$248
Lisinopril19$138
Spironolactone13$123
Carvedilol17$110
Furosemide11$59
Hydrochlorothiazide11$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$18,38927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 66 acute care providers in Rhode Island.

Other acute care in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →